Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Rockenstein

Showing results (21-30 of 197) with videos related to

Pageof 20
Sort By:
The Journal of Biological Chemistry|December 2, 2015
Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer DiseaseBrian Spencer, Rewati Potkar, Jeff Metcalf, et al.
Neuroreport|February 9, 2012
Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophyEdward Rockenstein, Kiren Ubhi, Chandra Inglis, et al.
Brain Research|February 13, 2025
Corrigendum to "Neurogranin binds alpha-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's disease" [Brain Res. 1591 (2014) 102-110]Andrew O Koob, Gideon M Shaked, Andreas Bender, et al.
Neuroreport|March 13, 2010
Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophyKiren Ubhi, Edward Rockenstein, Michael Mante, et al.
Experimental Neurology|November 26, 2009
Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic miceCorinne G Jolivalt, Rosemarie Hurford, Corinne A Lee, et al.
Journal of Neuroinflammation|September 20, 2012
Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in miceMarkus Britschgi, Yoshiko Takeda-Uchimura, Edward Rockenstein, et al.
Brain Research|December 3, 2014
Neurogranin binds α-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's diseaseAndrew O Koob, Gideon M Shaked, Andreas Bender, et al.
The Journal of Biological Chemistry|March 18, 2004
Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's diseaseMakoto Hashimoto, Pazit Bar-On, Gilbert Ho, et al.
Journal of Neuroscience Research|July 12, 2002
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promotersEdward Rockenstein, Margaret Mallory, Makoto Hashimoto, et al.
Journal of Alzheimer'S Disease : JAD|March 16, 2011
A longitudinal study of behavioral deficits in an AβPP transgenic mouse model of Alzheimer's diseaseDaniel Havas, Birgit Hutter-Paier, Kiren Ubhi, et al.
Pageof 20

Showing results (21-30 of 197) with videos related to

Sort By:
Pageof 20
The Journal of Biological Chemistry|December 2, 2015
Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer DiseaseBrian Spencer, Rewati Potkar, Jeff Metcalf, et al.
Neuroreport|February 9, 2012
Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophyEdward Rockenstein, Kiren Ubhi, Chandra Inglis, et al.
Brain Research|February 13, 2025
Corrigendum to "Neurogranin binds alpha-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's disease" [Brain Res. 1591 (2014) 102-110]Andrew O Koob, Gideon M Shaked, Andreas Bender, et al.
Neuroreport|March 13, 2010
Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophyKiren Ubhi, Edward Rockenstein, Michael Mante, et al.
Experimental Neurology|November 26, 2009
Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic miceCorinne G Jolivalt, Rosemarie Hurford, Corinne A Lee, et al.
Journal of Neuroinflammation|September 20, 2012
Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in miceMarkus Britschgi, Yoshiko Takeda-Uchimura, Edward Rockenstein, et al.
Brain Research|December 3, 2014
Neurogranin binds α-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's diseaseAndrew O Koob, Gideon M Shaked, Andreas Bender, et al.
The Journal of Biological Chemistry|March 18, 2004
Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's diseaseMakoto Hashimoto, Pazit Bar-On, Gilbert Ho, et al.
Journal of Neuroscience Research|July 12, 2002
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promotersEdward Rockenstein, Margaret Mallory, Makoto Hashimoto, et al.
Journal of Alzheimer'S Disease : JAD|March 16, 2011
A longitudinal study of behavioral deficits in an AβPP transgenic mouse model of Alzheimer's diseaseDaniel Havas, Birgit Hutter-Paier, Kiren Ubhi, et al.
Pageof 20